

Common Stock	02/17/2026	RSU Vest	Immunocore LLC (issuer)	<input type="checkbox"/>	11824	02/17/2026	Equity Compensation
--------------	------------	----------	-------------------------	--------------------------	-------	------------	---------------------

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Berman c/o Immunocore LLC 9801 Washingtonian Boulevard, Suite 800 Gaithersburg MD 20878	ADRs	12/04/2025	31341	1261788.66
David Berman c/o Immunocore LLC 9801 Washingtonian Boulevard, Suite 800 Gaithersburg MD 20878	ADRs	12/05/2025	572	22960.08
David Berman c/o Immunocore LLC 9801 Washingtonian Boulevard, Suite 800 Gaithersburg MD 20878	ADRs	11/26/2025	69404	2784488.48
David Berman c/o Immunocore LLC 9801 Washingtonian Boulevard, Suite 800 Gaithersburg MD 20878	ADRs	11/28/2025	5521	221336.89
David Berman c/o Immunocore LLC 9801 Washingtonian Boulevard, Suite 800 Gaithersburg MD 20878	ADRs	11/24/2025	100	4000
David Berman c/o Immunocore LLC 9801 Washingtonian Boulevard, Suite 800 Gaithersburg MD 20878	ADRs	11/25/2025	18020	721340.6

144: Remarks and Signature

Remarks

Date of Notice

02/18/2026

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

J.P. Morgan Securities LLC, Workplace Solutions, as Agent and Attorney in Fact for David Berman, Immunocore Holdings LLC

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)